bmy
BMY46.440USD
-0.440-0.94%
종가 05/09, 16:00（ET）시세는 15분 지연됩니다
94.51B시가총액
손실P/E TTM
자세한 내용은 Bristol-Myers Squibb Co 회사
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
회사 정보
회사 코드BMY
회사 이름Bristol-Myers Squibb Co
상장일Jul 05, 1929
설립일1933
CEODr. Christopher S. (Chris) Boerner, Ph.D.
직원 수34100
유형Ordinary Share
회계 연도 종료Jul 05
주소Route 206 And Province Line Road
도시PRINCETON
증권 거래소NYSE Consolidated
국가United States of America
우편 번호08543
전화16092524621
웹사이트https://www.bms.com
회사 코드BMY
상장일Jul 05, 1929
설립일1933
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
83.51K
+5.36%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.32K
+65.81%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
83.51K
+5.36%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.32K
+65.81%
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
지역별USD
이름
수익
비율
United States
34.10B
70.61%
International
13.20B
27.33%
other
996.00M
2.06%
사업별
지역별
사업별USD
이름
수익
비율
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
주주
업데이트 시간: Sat, Apr 26
업데이트 시간: Sat, Apr 26
주주 통계
유형
주주 통계
주주
비율
The Vanguard Group, Inc.
9.36%
BlackRock Institutional Trust Company, N.A.
4.80%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.98%
Other
75.08%
주주 통계
주주
비율
The Vanguard Group, Inc.
9.36%
BlackRock Institutional Trust Company, N.A.
4.80%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.98%
Other
75.08%
유형
주주
비율
Investment Advisor
36.57%
Investment Advisor/Hedge Fund
32.98%
Research Firm
2.84%
Pension Fund
2.49%
Bank and Trust
2.22%
Sovereign Wealth Fund
1.85%
Hedge Fund
1.69%
Insurance Company
0.18%
Individual Investor
0.05%
Other
19.13%
기관 주식 보유
업데이트 시간: Sun, Jan 19
업데이트 시간: Sun, Jan 19
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
4219
1.65B
81.22%
+21.37M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
2022Q4
4105
1.66B
77.92%
-72.60M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
189.02M
9.29%
+1.40M
+0.75%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
97.01M
4.77%
-7.46M
-7.14%
Dec 31, 2024
State Street Global Advisors (US)
95.14M
4.68%
+2.25M
+2.42%
Dec 31, 2024
JP Morgan Asset Management
63.10M
3.1%
+12.35M
+24.34%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
60.30M
2.96%
-729.93K
-1.20%
Dec 31, 2024
Capital International Investors
45.87M
2.25%
+3.22M
+7.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
44.39M
2.18%
+1.19M
+2.75%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
28.50M
1.4%
+12.26M
+75.55%
Dec 31, 2024
Fidelity Management & Research Company LLC
27.55M
1.35%
-9.07M
-24.78%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
First Trust NASDAQ Pharmaceuticals ETF
8.35%
Cullen Enhanced Equity Income ETF
5.49%
Invesco S&P Ultra Dividend Revenue ETF
4.94%
VictoryShares Free Cash Flow ETF
4.81%
VanEck Pharmaceutical ETF
4.81%
Tema Oncology ETF
4.61%
iShares U.S. Pharmaceuticals ETF
4.38%
Schwab U.S. Dividend Equity ETF
4.07%
SPDR S&P Pharmaceuticals ETF
3.65%
Brookstone Value Stock ETF
3.54%
더 보기
First Trust NASDAQ Pharmaceuticals ETF
비율8.35%
Cullen Enhanced Equity Income ETF
비율5.49%
Invesco S&P Ultra Dividend Revenue ETF
비율4.94%
VictoryShares Free Cash Flow ETF
비율4.81%
VanEck Pharmaceutical ETF
비율4.81%
Tema Oncology ETF
비율4.61%
iShares U.S. Pharmaceuticals ETF
비율4.38%
Schwab U.S. Dividend Equity ETF
비율4.07%
SPDR S&P Pharmaceuticals ETF
비율3.65%
Brookstone Value Stock ETF
비율3.54%
주식 배당금
지난 5년 동안 총
22.71B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음